Carthamus tinctorius L. extract activates insulin‐like growth factor‐I receptor signaling to inhibit FAS‐death receptor pathway and suppress lipopolysaccharides‐induced H9c2 cardiomyoblast cell apoptosis

Carthamus tinctorius L. (Compositae) is used in Chinese medicine to treat heart disease and inflammation. In our previous study, we found that C. tinctorius L. inhibited lipopolysaccharides (LPS)‐induced tumor necrosis factor‐alpha (TNF‐α) activation, JNK expression, and apoptosis in H9c2 cardiomyoblast cells. The present study was performed to investigate the protective effect of C. tinctorius extract (CTF) on LPS‐challenged H9c2 myocardioblast cell and to explore the possible underlying mechanism. Cell viability assay showed that LPS treatment decreased the cell viability of H9c2 cell, whereas CTF treatment reversed LPS cytotoxicity in a dose‐dependent manner, especially in the LPS + CTF 25 (μg/mL) group. LPS treatment‐induced apoptosis was determined by transferase‐mediated dUTP nick end labeling assay, and by Western blot. LPS‐induced apoptotic bodies were decreased following CTF treatment. Expression of TNF‐α, FAS‐L, FAS, FADD, caspase‐8, BID, and t‐BID was significantly increased in LPS‐treated H9c2 cells. In contrast, it was significantly suppressed by the administration of CTF extract. In addition, CTF treatment activates antiapoptotic proteins, Bcl‐2 and p‐Bad, and downregulates Bax, cytochrome‐c, caspase‐9, caspase‐3, and apoptosis‐inducing factor expression. Furthermore, CTF exerted cytoprotective effects by activating insulin‐like growth factor‐I (IGF‐I) signaling pathway leading to downregulation of the apoptotic proteins involved in FAS death receptor pathway. In addition, AG1024 and IGF‐I receptor (IGF‐IR) inhibitor and siRNA silencing reverses the effect of CTF implying that CTF functions through the IGF‐IR pathway to inhibit LPS‐induced H9c2 apoptosis. These results suggest that treatment with CTF extract prevented the LPS‐induced apoptotic response through IGF‐I pathway.     

Correction: Discovery of 8-prenylnaringenin from hop (Humulus lupulus L.) as a potent monoacylglycerol lipase inhibitor for treatments of neuroinflammation and Alzheimer’s disease

Correction for ‘Discovery of 8-prenylnaringenin from hop (Humulus lupulus L.) as a potent monoacylglycerol lipase inhibitor for treatments of neuroinflammation and Alzheimer’s disease’ by Min-Che Tung et al., RSC Adv., 2021, 11, 31062–31072, https://doi.org/10.1039/D1RA05311F.

The authors regret that the name of one of the authors (Hsing-Mien Hsu) was shown incorrectly in the original article. The corrected author list is as shown above.The authors also regret an incorrect version of Fig. 7 was included in the original article. The correct version of Fig. 7 is presented below.Open in a separate windowFig. 7The dose-dependent inhibitions of the identified inhibitors against hMAGL.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.     

Triterpenoids and aromatics from Derris laxiflora

Seven new compounds, O-trans-cinnamoylglutinol (1), 22β-hydroxy-12-oleanen-3-one (2), 15α,16α-epoxy-12-oleanen-3-one (3), 29-hydroxy-12-oleanene-3,22-dione (4), 22β,29-dihyroxy-12-oleanen-3-one (5), 2,3-(methylenedioxy)-4-methoxy-5-methylphenol (8), and 2,3,6-trimethoxy-5-methylphenol (9), as well as two first isolated from natural sources, 25-cycloartene-3,24-dione (6) and 24ξ-hydroxy-25-cycloarten-3-one (7), were characterized from Derris laxiflora. The structures of these compounds were determined by analysis of their spectroscopic data.     

Fetal nasal bone length and Down syndrome during the second trimester in a Chinese population

Objective:  The purpose of the present study was to build a database of reference ranges of fetal nasal bone length (NBL) in a Chinese population. The accuracy rate of detecting Down syndrome was also analyzed using fetal NBL as a marker.
Methods:  The control group of fetuses included 342 normal singleton pregnancies with no chromosomal or congenital anomalies. The present study was a cross-section study and the control group was used to construct percentile values of NBL from 13 to 29 gestational weeks of age. Two-dimensional ultrasonography was used for the nasal bone studies. Measurements of NBL were collected and each fetus contributed a single value to the reference sample. During the study period, 14 fetuses with Down syndrome were examined. Measurement of fetal NBL was made during amniocentesis, with gestational age ranging from 13 to 19 weeks.
Results:  From 342 normal fetuses with gestational age ranging from 13 to 29 weeks, reference ranges of NBL were constructed. The reference ranges were constructed from the 100(1 − p)% reference range:     , where Ŷ  = 25 − exp(3.58 − 0.044 ×  t  + 0.0006 ×  t ²), with Ŷ being the fitted mean of regression model and t being gestational age (weeks). Using fetal NBL, the regression model was Pr (Down syndrome) = exp( W )/[1 + exp( W )], where W  = 0.62–4.80 × NBL (multiples of the median) in predicting Down syndrome. Fetal NBL was found to have a sensitivity and specificity of 0.78 and 0.78, respectively, in predicting Down syndrome in the second trimester of pregnancy.
Conclusions:  Fetal NBL measurement can provide a simple and useful algorithm to predict Down syndrome during the second trimester of pregnancy.     

Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess?

OBJECTIVE: This retrospective study investigated the specificity of restricted water diffusion for the diagnosis of brain abscess. Two of five rim-enhancing brain masses with restricted water diffusion (apparent diffusion coefficient of 0.79 [10(-3) mm(2)/sec] or less) were brain abscesses, but diagnoses in the other cases were metastatic squamous cell carcinoma (two cases) and radiation necrosis. CONCLUSION: Although an important diagnostic sign, restricted water diffusion is not specific for brain abscess.     

MR imaging of pituitary adenomas after gamma knife stereotactic radiosurgery

OBJECTIVE: The purpose of this study was to evaluate the response of pituitary adenomas to radiosurgery as manifested by changes in size and appearance on serial MR imaging. MATERIALS AND METHODS: Over a mean follow-up period of 36 months, changes in 44 pituitary adenomas were assessed on 147 enhanced MR imaging studies. Prior surgery had been performed in 36 tumors (82%). RESULTS: At the time of radiosurgery, mean tumor volume was 5.9 +/- 0.8 cm(3) (mean diameter, 2.2 cm). The mean reduction in volume at last follow-up was 41% (+/- 5%, p < 0.001), and a decrease in tumor volume of 25-100% was observed in 34 tumors (77%). Mean reduction in tumor volume at 6 months after radiosurgery was 9% (p = 0.095); at 1 year, 24% (p < 0.001); at 2 years, 34% (p < 0.001); at 3 years, 41% (p < 0.001); and at 4 years, 50% (p = 0.008). Six months after radiosurgery a slight and transient increase in size was observed in 21% of tumors. During follow-up, neither decreased contrast enhancement nor cyst development was associated with changes in tumor volume. CONCLUSION: Tumor control was observed for most pituitary adenomas after radiosurgery and occurred gradually over a period of several years. A small increase in tumor size might be observed in the first 6 months after radiosurgery. In most cases, reductions in tumor size were not accompanied by a change in contrast enhancement or cyst formation.     

Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium

PurposePlatelet function test (PFT) results and genotype hold unique prognostic implications in East Asian patients. The aim of the PTRG-DES (Platelet function and genoType-Related long-term proGnosis in Drug-Eluting Stent-treated Patients with coronary artery disease) consortium is to assess the clinical impact thereof on long-term clinical outcomes in Korean patients with coronary artery disease during dual antiplatelet therapy (DAPT) including clopidogrel.Materials and MethodsSearching publications on the PubMed, we reviewed clopidogrel treatment studies with PFT and/or genotype data for potential inclusion in this study. Lead investigators were invited to share PFT/genotype results, patient characteristics, and clinical outcomes to evaluate relationships among them.ResultsNine registries from 32 academic centers participated in the PTRG-DES consortium, contributing individual patient data from 13160 patients who underwent DES implantation between July 2003 and August 2018. The PTRG-PFT cohort was composed of 11714 patients with available VerifyNow assay results. Platelet reactivity levels reached 218±79 P2Y12 reaction units (PRU), and high on-clopidogrel platelet reactivity based on a consensus-recommended cutoff (PRU >208) was observed in 55.9%. The PTRG-Genotype cohort consisted of 8163 patients with candidate genotypes related with clopidogrel responsiveness. Of those with cytochrome P450 (CYP) 2C19 genotype, frequencies of carrying one and two loss-of-function allele (s) (^*2 or ^*3) were 47.9% (intermediate metabolizers) and 14.2% (poor metabolizers), respectively.ConclusionThe PTRG-DES consortium highlights unique values for on-clopidogrel platelet reactivity and CYP2C19 phenotype that may be important to developing optimal antiplatelet regimens in East Asian patients.Trial RegistrationClinicalTrials.gov Identifier: {"type":"clinical-trial","attrs":{"text":"NCT04734028","term_id":"NCT04734028"}}NCT04734028.     

Laparoscopic pancreaticoduodenectomy combined with minilaparotomy

Laparoscopic pancreatic surgery is evolving rapidly; however, the surgical treatment of periampullary tumors is still fraught with challenges, such as technical difficulty and the appropriateness of oncologic treatment for these patients. We describe how we performed laparoscopic pancreaticoduodenectomy (LPD) combined with minilaparotomy successfully in six consecutive patients. This procedure consisted of two surgical phases: safe laparoscopic surgery, including the Kocher maneuver, tunneling behind the pancreatic neck, and dissecting along the uncinate process with magnified vision; and a secure open approach with complete skeletonization of the hepatoduodenal ligament and alimentary tract reconstruction, performed similarly to conventional pancreaticoduodenectomy, under direct visualization through the minilaparotomy. By performing this procedure, we combined a safe and secure minilaparotomy approach under direct vision with a less invasive laparoscopic approach providing a magnified image. Our experience demonstrates that LPD combined with minilaparotomy is technically feasible for selected patients with periampullary tumors.     

Lipomatous meningioma: Diagnostic pitfalls and pathological updates

We present a case of histologically confirmed lipomatous meningioma, the first to our knowledge reported in Hong Kong. A 75‐year‐old woman presented to us with on and off dizziness for 1 month. Computed tomography (CT) of the brain showed an extra‐axial mass lesion containing fat and solid enhancing foci at her right frontal region. The definitive diagnosis could be made preoperatively. Postoperative histological examination of the tumour revealed the diagnosis of lipomatous meningioma. We have reviewed the literature and discussed the diagnostic clues, clinical presentation and pathology of this rare tumour.     

Development and validation of an LC–ESI–MS/MS method for simultaneous determination of levodopa, dopamine, L-α-methyldopa and 3-O-methyldopa in rat plasma

Parkinson??s disease (PD) is a progressive degenerative disorder of the central nervous system. Levodopa (L-dopa), dopamine precursor is the most effective therapeutic drug for PD patients. Levodopa (LDP) and its three metabolites in rat plasma were determined using high performance liquid chromatography coupled with tandem mass spectrometry (LC?CMS/MS). Method validation was conducted in terms of linearity, accuracy, precision, recovery, specificity, limit of detection, limit of quantification and stability. Correlation coefficients (r ²) were above 0.9965. The intra-day accuracy values at LLOQ (low limit of quantification), LQC (low quality control), MQC (medium quality control) and HQC (high quality control) levels were 85.7?C103.3, 96.5?C105.1, 90.7?C100.1 and 94.2?C101.3?%, respectively. The inter-day accuracy values at LLOQ, LQC, MQC and HQC levels were 77.6?C112.0, 91.1?C109.3, 84.3?C101.0 and 88.2?C103.9?%, respectively. The coefficient of variation (RSD) values of both intra- and inter-day results were within 6.7 and 8.5?%, respectively. The recoveries (mean?±?%SD) for LLOQ, LQC, MQC and HQC were 82.7?±?3.7?C113?±?2.8?%, 86.6?±?5.7?C110.3±3.4?%, 90.9?±?3.6?C106?±?6.5 and 89.7?±?4.5?C97.4?±?6.7?%, respectively. The coefficient of variation (RSD) values of both intra- and inter-day results were within 6.7 and 8.5?%, respectively. The validated LC?CMS/MS method was applied successfully to the measurement of LDP and its metabolites in the rat plasma samples.